Stay updated with the latest peptide news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on peptide topics.
Bengaluru: Biocon Limited has achieved a regulatory milestone in the United States, reinforcing its presence in the global diabetes treatment market. Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approval enables the company to market the drug for adults with type 2 diabetes mellitus, expanding its footprint in one of the world's largest pharmaceutical markets. T ...Read More >
New Delhi, Dec 15 (PTI) Biocon Ltd on Monday said it has launched its diabetes and chronic weight management injection, Liraglutide, in the Netherlands through its distribution partner, Pharmamedic BV. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management, Biocon said in a statement. Liraglutide is a synthetic analog of GLP-1 peptide (glucagon-like peptide-1) that helps lower blood sugar levels an ...Read More >
The investment is part of the company's planned capital expenditure, reflecting strong business momentum, a robust late-stage development pipeline, and increasing demand for scalable capacity across CMC development and manufacturing. Sai Life Sciences Ltd. on Monday, October 27, announced that it is setting up a new research and development (R&D) block for chemical, manufacturing, and controls processing Hyderabad campus. The five-storeyed facility, designed as a green building, is expected to ...Read More >
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world first regulatory approval from India Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. * Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a ...Read More >
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. Also Read | 'Coolie' X Review: Rajinikanth's 'One-Man Show' With Nagarjuna's Stylish Act and Anirudh Rav ...Read More >
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world first regulatory approval from India Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. * Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a ...Read More >
New Delhi, Jul 12 (PTI) Anthem Biosciences has raised Rs 1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription. Some of the investors that participated in the anchor book are -- Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF, according to a circular uploaded on BSE's webs ...Read More >
New Delhi, Jul 9 (PTI) Anthem Biosciences on Wednesday fixed a price band of Rs 530 to Rs 570 for its Rs 3,395-crore initial public offering (IPO). At the upper end of the price band, the company's evaluation exceeds Rs 31,800 crore. The initial share-sale will be open for public subscription during July 14-16 and the one-day bidding for anchor investors is scheduled for July 11, the company said. The proposed IPO is entirely an offer-for-sale (OFS) worth Rs 3,395 crore by promoters, investor ...Read More >
American entrepreneur Bryan Johnson, known for his quest to reverse aging, experienced the effects of Mumbai's air pollution during his India tour. Promoting his book Don't Die, Johnson detailed his discomfort despite using air purifiers and masks. He adhered to his rigorous health routine, carrying all his meals and supplements for the six-day trip. The visit included an exclusive meetup with prominent figures like Zomato CEO Deepinder Goyal, showcasing his dedication to health and longevity ad ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.